CULLINAN THERAPEUTICS INC (CGEM) Stock Overview
NASDAQ:CGEM - US2300311063 - Common Stock
CGEM Key Statistics, Chart & Performance
The current stock price of CGEM is 7.54 USD. In the past month the price decreased by -1.69%. In the past year, price decreased by -61.53%.
CGEM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.87 | 371.68B | ||
| AMGN | AMGEN INC | 13.19 | 154.89B | ||
| GILD | GILEAD SCIENCES INC | 14.6 | 140.17B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.08 | 100.25B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 61.55B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.53B | ||
| ARGX | ARGENX SE - ADR | 76.83 | 43.59B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.16 | 36.38B | ||
| INSM | INSMED INC | N/A | 28.77B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.04B | ||
| NTRA | NATERA INC | N/A | 23.09B | ||
| BIIB | BIOGEN INC | 8.26 | 19.38B |
Related stock screener links
About CGEM
Company Profile
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 111 full-time employees. The company went IPO on 2021-01-08. The company has built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in autoimmune diseases and cancer. Its portfolio includes a range of modalities. Its pipeline includes CLN-978, CLN-619, Zipalertinib (CLN-081/TAS6417), CLN-049, and CLN-617. CLN-978 is a CD19xCD3 T cell engager being developed for autoimmune diseases. CLN-619 is a monoclonal antibody that stabilizes expression of MICA/B on the tumor cell surface to promote tumor cell lysis mediated by cytotoxic innate and adaptive immune cells. Zipalertinib (CLN-081/TAS6417) is an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor. CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-617 is a fusion protein combining two potent antitumor cytokines, interleukin-2 and interleukin-12 with tumor retention domains for the treatment of solid tumors.
Company Info
CULLINAN THERAPEUTICS INC
One Main Street, Suite 1350
Cambridge MASSACHUSETTS 02142 US
CEO: Owen Hughes
Employees: 111
Phone: 16174104650
CULLINAN THERAPEUTICS INC / CGEM FAQ
What is the stock price of CULLINAN THERAPEUTICS INC today?
The current stock price of CGEM is 7.54 USD. The price decreased by -0.92% in the last trading session.
What is the ticker symbol for CULLINAN THERAPEUTICS INC stock?
The exchange symbol of CULLINAN THERAPEUTICS INC is CGEM and it is listed on the Nasdaq exchange.
On which exchange is CGEM stock listed?
CGEM stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CULLINAN THERAPEUTICS INC stock?
16 analysts have analysed CGEM and the average price target is 27.88 USD. This implies a price increase of 269.76% is expected in the next year compared to the current price of 7.54. Check the CULLINAN THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CULLINAN THERAPEUTICS INC worth?
CULLINAN THERAPEUTICS INC (CGEM) has a market capitalization of 445.39M USD. This makes CGEM a Small Cap stock.
How many employees does CULLINAN THERAPEUTICS INC have?
CULLINAN THERAPEUTICS INC (CGEM) currently has 111 employees.
What are the support and resistance levels for CULLINAN THERAPEUTICS INC (CGEM) stock?
CULLINAN THERAPEUTICS INC (CGEM) has a support level at 7.41 and a resistance level at 7.63. Check the full technical report for a detailed analysis of CGEM support and resistance levels.
Should I buy CULLINAN THERAPEUTICS INC (CGEM) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CGEM, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CGEM, evaluating the profitability, health, valuation and growth aspects
- CULLINAN THERAPEUTICS INC (CGEM) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CULLINAN THERAPEUTICS INC (CGEM) Sales and EPS estimates to see what analysts future expectations are.
- CULLINAN THERAPEUTICS INC (CGEM) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CULLINAN THERAPEUTICS INC (CGEM) Insider and Institutional Ownership to learn about the owners and their transactions.
- CULLINAN THERAPEUTICS INC (CGEM) Stock Chart to make your own analysis
- CULLINAN THERAPEUTICS INC (CGEM) Latest news and press-releases to stay up to date.
Does CULLINAN THERAPEUTICS INC (CGEM) stock pay dividends?
CGEM does not pay a dividend.
When does CULLINAN THERAPEUTICS INC (CGEM) report earnings?
CULLINAN THERAPEUTICS INC (CGEM) will report earnings on 2025-11-05, before the market open.
What is the Price/Earnings (PE) ratio of CULLINAN THERAPEUTICS INC (CGEM)?
CULLINAN THERAPEUTICS INC (CGEM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.23).
What is the Short Interest ratio of CULLINAN THERAPEUTICS INC (CGEM) stock?
The outstanding short interest for CULLINAN THERAPEUTICS INC (CGEM) is 12.26% of its float. Check the ownership tab for more information on the CGEM short interest.
CGEM Technical Analysis
CGEM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CGEM. No worries on liquidiy or solvency for CGEM as it has an excellent financial health rating, but there are worries on the profitability.
CGEM Financial Highlights
Over the last trailing twelve months CGEM reported a non-GAAP Earnings per Share(EPS) of -3.23. The EPS decreased by -5.56% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -39.74% | ||
| ROE | -42.01% | ||
| Debt/Equity | 0 |
CGEM Forecast & Estimates
16 analysts have analysed CGEM and the average price target is 27.88 USD. This implies a price increase of 269.76% is expected in the next year compared to the current price of 7.54.